AI, IP and Your Healthcare: And You Thought the Doctor’s Exam Was Intrusive!
AI is the next big thing, and most developers want to protect those programs and systems. The answer is intellectual property protection and specifically patent protection.
DeepMind has unlocked protein-based medicine – what does that mean for drug patents?
One of science's great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind's discoveries while protecting their own?
As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality
The U.S. Supreme Court heard oral arguments Monday on the constitutionality of the Patent Trial and Appeal Board, an essential piece of the United States patent litigation puzzle and favored tool of generic and biosimilar patent challengers since its formation in 2012.
Trial and error, or the problem of clinical trial data exclusivity
Clinical trials are a necessary part of the creation and marketing of new drugs, but the way we incentivize them contributes to our current system of exorbitant pricing.
What SCOTUS’s refusal to review cases on patent-eligible subject means
A patent lawyer takes a closer look at the guidance on how to meet patent-eligibility standards using conclusions from recent court cases, including those denied by the Supreme Court.
American Well loses patent claim against Teladoc, plans appeal
American Well has already fired back. "This is Borders versus Amazon for healthcare," said Chairman and CEO Dr. Ido Schoenberg.
presented by
Could QuantalX’s Device Make Managing Brain Health Easier?
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.
Which drugs are going off-patent in 2016?
This will be a year in which generic drugmakers will have plenty of fodder - more than two dozen major drugs are going off-patent in 2016.
Medical device patent law: Changes, subtleties and tricks-of-the-trade secrets
The patent protection landscape’s been turned on its head in the past couple years, ever since the Leahy-Smith America Invents Act went into effect. A discussion at trade group Biocom’s DeviceFest in San Diego this week addressed some of these changes and subtleties as they apply to medical device companies: “Gone are the days of storing the notes of […]